Researchers found that women with breast cancer were less likely to have two versions of the TCATA haplotype, associated with increased IL-10 expression. High levels of IL-10 may be protective against breast cancer due to its anti-angiogenic effects.
A new test using Ki67 levels has been shown to predict the aggressiveness of breast cancer in early stages with high accuracy. The test correlates with tumor size, nodal status, and other parameters, providing valuable information for clinicians to make informed treatment decisions.
A daily bioadhesive buccal tablet containing 50mg of miconazole has been shown to be as effective as a four-times-daily mouth gel in treating oropharyngeal candidiasis among head and neck cancer patients. This simpler treatment schedule may improve quality of life and increase patient compliance.
A new study finds that oral capecitabine plus oxaliplatin shows comparable efficacy and toxicity profiles to traditional intravenous chemotherapy, offering a more convenient treatment option for patients. The regimen has shown similar response rates and overall survival, with benefits in terms of patient autonomy and quality of life.
A phase I study has shown early promise for a cancer-killing virus targeting colorectal cancer. The virus, NV1020, selectively kills cancer cells while sparing normal tissue, leading to improved CEA reductions and median survival times of up to 23 months.
Researchers analyzed 3,500 breast cancer patients to identify factors associated with relapse. Patients with ER+/PgR- status, HER2 overexpression, or fewer than 10 positive axillary nodes did not show increased risk of relapse. Massive involvement of axillary nodes was linked to a higher risk of developing distant or local relapse.
A survey of 291 oncologists from 55 countries found that increased funding for research and clinical research were the top priorities for improving cancer care. Oncologists also emphasized the importance of interdisciplinary cooperation and medical training to enhance treatment outcomes.
The report reveals that nearly 2.9 million new cases of cancer were diagnosed in Europe in 2004, with lung cancer being the most common form. Breast cancer is also on the rise, while stomach cancer rates are falling. The study emphasizes the need for a joint European effort to combat these diseases.
A third of European cancer patients use CAM, with women, younger patients, and those with poor prognosis using it more often. The most commonly used CAM therapies were herbs, homeopathy, and spiritual therapies.
US researchers found that oleic acid in olive oil suppresses the Her-2/neu oncogene, a key driver of aggressive breast cancer. The study suggests that dietary interventions based on oleic acid may delay or prevent drug resistance in patients with high levels of this gene.
A large population study has found that most ovarian cancers in families with at least one woman with breast cancer are not related to BRCA1/2 mutations. Instead, other factors may contribute to the increased risk of ovarian cancer in these families.
The World Health Organization's Framework Convention on Tobacco Control aims to reduce tobacco use through measures such as banning advertising, warning labels, and smoke-free places. European countries are called upon to swiftly ratify the treaty to combat lung cancer and protect public health.
New research suggests that cancer-related fatigue is more closely tied to depression and impaired physical performance than previously thought. A study of 70 patients in remission found no correlation between fatigue and various physiological markers, but significant associations with depression and physical performance.
The European Society for Medical Oncology (ESMO) has launched a new charitable foundation with the goal of making the best treatment available to every cancer patient. The ESMO Foundation will provide much-needed funds for education, research, and patient care.
A survey of 32 popular English-language websites found that many promoted unproven therapies and some were even dangerous, while others provided valuable and reliable information. The researchers recommend a seal of approval scheme for complementary and alternative websites to minimize harm.
The European Society for Medical Oncology survey found that stem cell transplants for breast cancer decreased from 2,629 in 1997 to 330 in 2002. The use of autologous transplants continued to rise for certain types of solid tumours, while allogenic transplants saw a slight increase, particularly for metastatic tumours.
A recent report shows a significant decline in stomach cancer rates across Europe, with falls seen in younger and middle-aged populations. The downward trend is attributed to improved diet, better food preservation, reduced Helicobacter pylori infection, and lower smoking rates.
A Phase II trial of Herceptin combined with chemotherapy found no significant difference in survival times between the treatment and control arms. However, a small subgroup of patients with extremely high levels of HER2 over-expression showed improved response rates and longer disease progression-free periods.
The report analyzes survival data from 23,000 children diagnosed between 1990 and 1994, showing significant differences in overall cancer survival rates. The Nordic countries had the highest survival figures for four major childhood tumor types, with an average five-year survival rate of 71.8% across all European countries.
A study by French researchers found that young breast cancer patients who undergo lumpectomy have a higher risk of late recurrence compared to those who opt for mastectomy. The risk is particularly high among women under 40 years old.
The EU's Europe Against Cancer Programme has shown promising results in reducing cancer deaths across most European countries. However, tobacco use still poses a significant threat to public health, with many countries experiencing declining trends in cancer death rates while others struggle with rising rates.
Pregnant women should undergo thorough breast examinations to detect breast cancer, as diagnosis is often delayed due to hormonal changes. Ultrasonography is the best method for detecting cancerous lumps during pregnancy.
Researchers have developed a new treatment strategy that combines chemo-radiation and surgery to prevent recurrence of rectal cancer. The study, conducted by Professor Andres Cervantes' team, demonstrated excellent results with no local relapse after two years.
The European Society for Medical Oncology (ESMO) presented a new drug, ET743, which has shown promising results in treating advanced ovarian cancer. In a clinical trial, the drug reduced tumors in 47% of patients, with some experiencing complete responses.
A study by German researchers found nearly half breast cancer patients struggle with incomprehensible or incomplete information, while over half want more opportunities to discuss their treatment. The report emphasizes the importance of improving communication between medical staff and patients.
Researchers used Diffusion-Weighted Magnetic Resonance Imaging (DWMRI) to visualize and measure water characteristics in mouse tumors before and after chemotherapy. They found a significant correlation between water diffusion properties prior to treatment and subsequent tumor growth rate.
Early results of North American trials of oxaliplatin show a 70% delay in tumour progression and significant improvement in symptoms for patients with advanced bowel cancer. The US FDA has approved the drug for use in these patients.
A new trial shows that high-dose chemotherapy has no significant benefits for women with severe breast cancer. However, molecularly targeted drugs in combination with chemotherapy show promising results.
Screening for colorectal cancer is vital for early detection, with a significant reduction in mortality rates associated with early detection. Current techniques like colonoscopy are effective but expensive, prompting the need for alternative methods.
A study by Dr Zeba Aziz found that socio-economic status significantly impacts breast cancer treatment and survival rates in developing countries. Women from lower socio-economic backgrounds often delay seeking medical help, resulting in delayed diagnosis and inadequate treatment, leading to poor survival rates.
A study involving 83 elderly women found that patients with depression, limited autonomy, and institutional living are at risk of toxicity and reduced treatment effectiveness. Dr. Gilles Freyer's research aims to evaluate risks and benefits for elderly patients with advanced ovarian cancer.
A ESMO survey found that almost all oncologists (92%) believe dying patients should receive anti-tumor therapy alongside end-of-life care. However, less than half routinely coordinate patient care or collaborate with support teams.
Research by Dr Anne Chantal Braud and her team has shown that older women with breast cancer can tolerate powerful medication, contradicting initial expectations. The study examined the effects of surgery, radiotherapy, chemotherapy, and hormone therapy on 179 women over 70 years old.
A new information structure called Point of Information and Support (PIS) has been shown to reduce patients' anxiety and depression by providing personalized health information. The PIS comprises a library with booklets, videos, and essential information about cancer types and drugs.
A new programme, GOALS, has been developed to help cancer patients discuss their condition with family, friends, and colleagues. The five-step protocol focuses on identifying the right place and moment for conversation, acknowledging emotions, and developing a strategy to open discussion.
A recent study suggests that cancer patients who have smoking-related cancers such as lung, head and neck or bladder cancer are more likely to quit smoking. These patients were also more likely to have made attempts to quit in the previous 12 months and had not received radiotherapy or surgery.
As new genetic components are identified, clinical services must adapt to cope with the increasing demand. The role of genetic information in managing inherited cancers is becoming increasingly important, enabling tailored therapies for individual patients.
A study by Dr. Tony Mok and his team investigates the potential benefits of Chinese herbal medicine in reducing chemotherapy-induced toxicity in breast and colon cancer patients. Early results show a moderate reduction in symptoms, paving the way for further research into this alternative treatment approach.
Key findings from the ESMO Congress emphasize the need for better care and communication in cancer treatment. Patients must be informed and involved in their treatment decisions, while healthcare professionals should prioritize empathy and understanding. A European cancer patient coalition is proposed to amplify patients' voices.
A patient's view on clinical trials highlights the importance of thorough explanations, confidentiality, and compassionate communication. Sylvia Achin emphasizes that patients risk losing their priorities, relationships, and even support when faced with a life-threatening disease like cancer. Effective communication can help alleviate ...
A new chip technology is being developed to analyze cancer genes, promising faster and more accurate diagnoses. The technology uses DNA microarrays to screen thousands of genes simultaneously, allowing for quicker testing than current methods.
A study by Professor Lesley Degner found that Canadian women with breast cancer and men with prostate cancer fare better emotionally and socially due to their positive attitude towards illness. The most important information patients want is 'What are my chances of a cure?' and 'How far has my disease spread?'.
A study by Professor Lesley Fallowfield found that psychosocial discussions are often overlooked in cancer treatment consultations. Training can help doctors and nurses discuss personal and sexual issues comfortably and sensitively, improving patient outcomes.
Professor Edzard Ernst urges oncologists to be open to alternative medicines, as desperation drives patients to try anything. He warns that some therapies can be dangerous and advises patients to consult with healthcare professionals before trying new treatments.
A new phase III multi-national European trial involving 618 patients with advanced non small-cell lung cancer found that cisplatin and paclitaxel improved survival rates compared to carboplatin and paclitaxel. The study suggests that cisplatin-based chemotherapy remains the preferred standard treatment for lung cancer in Europe.
A study of 53 IRB members found that while most prioritize the development of effective cancer therapies, individual approaches to weighing pros and cons vary widely. Only 12% use systematic risk-benefit calculations, with many relying on impression-based or practical considerations.
The study found significant variations in cancer prevalence across European countries, with high rates in Sweden, Switzerland, and Germany, and low rates in Poland, Estonia, Slovakia, and Slovenia. The research team suggests that cancer prevalence is closely linked to economic development and survival rates.
Researchers found that elevated troponin I levels may predict future heart failure in cancer patients, even if the heart appears to be functioning normally. ACE inhibitors have shown promise in restoring cardiac function and preventing cardiotoxicity in breast cancer patients treated with anthracyclines.
A study by cancer experts found that the response rate of tumours to a new drug decreases over time due to 'wish bias', an unconscious tendency for doctors to expect better results. The research team recommends double-blinded trials to avoid this bias and ensure objectivity in medical research.
Researchers warn that patients with testicular cancer are living long enough to suffer from life-threatening side effects, including cardiovascular disease. Studies found that nearly a third had abnormal heart function, while over 80% had raised cholesterol levels.